There are 119 resources available
49P - Antitumor effects of cationic dendritic molecules and their complexes with microRNA in glioblastoma stem-like cells
Presenter: Nadezhda Knauer
Session: e-Poster Display session
46P - AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2_ Inhibitor, for the Treatment of Renal Cell Carcinoma
Presenter: Kenneth Lawson
Session: e-Poster Display session
41P - The SARS-CoV-2 vaccine and enrollment of patients with cancer in Phase I trials: the experience at Institute Gustave Roussy
Presenter: Laila Belcaid
Session: e-Poster Display session
50P - Targeting the renin-angiotensin system in gastric cancer therapeutics
Presenter: Surenjav Chimed
Session: e-Poster Display session
1P - Sitravatinib + Tislelizumab in Patients with Anti-PD-(L)1 Refractory/Resistant Metastatic Non-small Cell Lung Cancer (NSCLC)
Presenter: No Gao
Session: e-Poster Display session
2P - Sitravatinib + Tislelizumab in Patients with Metastatic Non-small Cell Lung Cancer (NSCLC)
Presenter: Zhou Qing
Session: e-Poster Display session
3P - Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)
Presenter: Sumita Pradhan
Session: e-Poster Display session
9P - Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase
Presenter: Elizabeth Lee
Session: e-Poster Display session
8P - Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer
Presenter: Stephanie Lheureux
Session: e-Poster Display session
10P - SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer
Presenter: Yongxia Zhu
Session: e-Poster Display session